
Around 25 percent of US Medicare spending occurs in the last year of life. Does that mean society is throwing large amounts of medical treatment at some patients in a futile, if noble, effort to extend lives that are bound to end soon?
A study coauthored by economics professor Amy Finkelstein offers a resounding answer: No.
After examining millions of medical records, the researchers found that although Medicare spending is concentrated among people who end up dying, little of it goes to patients whose death within the year was judged highly likely. For example, less than 5 percent is applied to patients in the single highest-risk percentile—and their predicted one-year mortality rate is still just 46 percent.
“Very little money is spent on people who we know with high probability are going to die in a short amount of time,” says Finkelstein.
The study used machine learning to evaluate the impact of a range of variables, producing a probability of death within one year for each patient. It revealed that fewer than 10 percent of people who die in a given year have a predicted one-year mortality rate over 50 percent. And even when people are admitted to a hospital in their last year of life, fewer than 4 percent have a predicted one-year mortality rate of 80 percent or higher at the time of admission.
The study shows that even relatively low-mortality health scenarios for the elderly will include some deaths—not that individual treatment decisions represent long-shot cases.
Keep Reading
Most Popular
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.